Utility of Heidelberg Retina Tomograph in Monitoring Glaucoma Progression

The recruitment status of this study is unknown because the information has not been verified recently.
Verified September 2007 by University Health Network, Toronto.
Recruitment status was  Recruiting
Glaucoma Research Society of Canada
Information provided by:
University Health Network, Toronto
ClinicalTrials.gov Identifier:
First received: January 19, 2007
Last updated: September 28, 2007
Last verified: September 2007

Glaucoma is a chronic disease defined by characteristic changes in the optic nerve associated initially with loss of peripheral vision and is treated by lowering intraocular (inside the eye) pressure. It has been reported that noticeable changes to the optic nerve caused by glaucoma may occur several years before changes in vision are noticed. Since changes to the optic nerve and other eye structures due to glaucoma are irreversible, it is important to develop tools for the earliest possible detection of changes due to glaucoma.

The Heidelberg Retina Tomograph (HRT) is a device that is used to produce a three-dimensional map of the optic nerve and retina, and can be used to detect changes in the optic nerve and retina over time. In previous studies, it has been shown to be useful for the detection of changes due to glaucoma. However, the HRT when compared to other techniques to evaluate the optic nerve such as stereophotography, was found to only somewhat agree.

The current study will compare HRT to stereophotography to determine how good each one is at looking and documenting changes in the optic nerve over time due to glaucoma. Using HRT to initiate early topical medication or to change management requires knowing how well HRT results predict the development of visual loss. Accordingly, the results of this study may affect the management of glaucoma patients by optimizing the follow-up of people with this condition and by initiating appropriate and more individualized treatments. Early treatment is crucial for preventing further visual loss in patients with glaucoma or ocular hypertension (high pressure inside the eye).

Ocular Hypertension

Study Type: Observational
Study Design: Observational Model: Defined Population
Time Perspective: Longitudinal

Resource links provided by NLM:

Further study details as provided by University Health Network, Toronto:

Study Start Date: August 2006
Detailed Description:

In glaucoma, treatment decisions depend on the development of morphologic and functional damage. Therefore, damage serves as an indicator of management. Commonly, progression is determined by various perimetric techniques.

However, it has been reported that clinically detectable glaucomatous structural alteration of the ONH may precede the development of reproducible white on white and blue on yellow visual field defects by up to several years.

The HRT is a confocal scanning laser tomography device that creates a three-dimensional topographic analysis of the ONH and the peripapillary retina and includes a statistical analysis to evaluate structural change over time.

This technique showed good sensitivity and high specificity in detecting glaucoma progression when tested using computer simulation. The same good results were obtained by the same authors, in another study, in a small subgroup of 16 patients who were monitored for glaucomatous progression by both HRT and ONH stereophotographs for approximately 5.5 years.

However, in our recent retrospective study, our results demonstrated only fair agreement between HRT and clinical judgment of ONH stereophotographs for progression in glaucoma, for a mean follow-up time with HRT of 2.62 years. Although, the evaluation of the ONH stereophotographs is necessarily subjective, it is widely accepted and has been shown to be effective for evaluating change. Using the stereophotographs assessments as the "reference standard", the HRT sensitivity was 78% and the specificity to 70%. The positive predictive value of the HRT was 47.8%, while the negative predictive value was 90.3%.

According to the results of this study if the frequency of true positives and false positives does not change with longer follow-up, treatment decisions would be based on a test that may be in error 52.2% of the time.

Accordingly, our previous - and other studies - study demonstrated only fair agreement between HRT and clinical judgment of ONH stereophotographs for progression in glaucoma. At present, the available evidence does not appear to be sufficient to show that the addition of HRT improves the ability to predict the development of clinical optic disc change and/or visual field loss.

Therefore the aim of the current study is to investigate the clinical significance of the HRT in monitoring glaucoma progression. In other words we will investigate how well HRT results for glaucomatous progression are able to predict the future development of optic disc and/or visual field changes in patients with OHT and glaucoma.


Ages Eligible for Study:   20 Years to 80 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Best-corrected visual acuity of 20/40 or better
  • Subjects determined to have OHT or glaucoma
  • Spherical refraction within 6.0 D with plus or minus sphere, and cylinder within 3.0 D with plus or minus cylinder
  • Subjects that show progression on the HRT
  • subjects stable on ONH stereophotographs
  • subjects with stable and reliable visual fields
  • Subjects willing to make the required visits for the study
  • Subjects tolerant to dilating drops

Exclusion Criteria:

  • A suspicion or actual defect in the visual field of the eye being tested that is explained by the patient's ocular status or history, other than glaucoma
  • Any history of disease or use of medication that may affect visual field reliability
  • Past history of stroke or diabetic retinopathy
  • Inability of the pupils to be dilated to at least 4 mm for the screening visit
  • Inability to undergo either perimetry test or the ophthalmic examination
  • Inability to undergo adequate or better quality stereophotographs
  Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT00424996

Contact: Graham E Trope, PhD, FRCSC 416-603-5317 Graham.Trope@uhn.on.ca
Contact: Dimitrios Kourkoutas, MD +30 210 7664947 d_kourkoutas@hotmail.com

Canada, Ontario
University of Toronto; Toronto Western Hospital Recruiting
Toronto, Ontario, Canada, M5T 2S8
Contact: Graham E Trope, PhD, FRCSC    (416) 603-5317    Graham.Trope@uhn.on.ca   
Contact: Yvonne M Buys, MD, FRCSC    (416) 603-5682    y.buys@utoronto.ca   
Sub-Investigator: Dimitrios Kourkoutas, MD         
Principal Investigator: Yvonne M Buys, MD         
Sub-Investigator: Graham E Trope, PhD         
Sub-Investigator: John Flanagan, PhD         
Sub-Investigator: Carmen Balian, BSc         
Sponsors and Collaborators
University Health Network, Toronto
Glaucoma Research Society of Canada
Principal Investigator: Yvonne Buys, MD, FRCSC University of Toronto, Department of Ophthalmology; Toronto Western Hospital, Toronto, Ontario, Canada
Study Director: Graham E Trope, PhD, FRCSC University of Toronto, Department of Ophthalmology; Toronto Western Hospital, Toronto, Ontario, Canada
Study Chair: John Flanagan, PhD University of Toronto, Department of Ophthalmology; Toronto Western Hospital, Toronto, Ontario, Canada
  More Information

ClinicalTrials.gov Identifier: NCT00424996     History of Changes
Other Study ID Numbers: UHNToronto
Study First Received: January 19, 2007
Last Updated: September 28, 2007
Health Authority: Canada: Health Canada

Additional relevant MeSH terms:
Ocular Hypertension
Eye Diseases
Vascular Diseases
Cardiovascular Diseases

ClinicalTrials.gov processed this record on April 14, 2014